AbbVie: Multiple Myeloma trials

The registry lists 41 Multiple Myeloma studies with AbbVie as lead sponsor. 8 are open to participants now and 8 have results posted.

Phase 1 25Phase 2 16Phase 3 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07728188Phase 3
• A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)RecruitingNCT07409246Phase 1
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07095452Phase 2/3
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingNCT06953960Phase 1/2
• Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06896916Phase 1
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
• A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT05650632Phase 1
• Expanded Access to VenetoclaxAvailableNCT03123029
• A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03567616Phase 2Results posted
• Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaCompletedNCT02902965Phase 2Results posted
• A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyCompletedNCT02755597Phase 3Results posted
• Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple MyelomaTerminatedNCT02548962Phase 1/2Results posted
• Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01962792Phase 1/2Results posted
• Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01794520Phase 1/2Results posted
• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT01478581Phase 2Results posted
• A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple MyelomaCompletedNCT00742560Phase 2Results posted
• Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06223516Phase 1
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
• A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 TabletsActive, not recruitingNCT05308654Phase 1
• A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in JapanActive, not recruitingNCT05286229Phase 1
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05259839Phase 1
• Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple MyelomaTerminatedNCT04895410Phase 1
• Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)CompletedNCT04721002
• Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT04570631Phase 1
• A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple MyelomaTerminatedNCT04178902Phase 1
• A Study of TNB-383B in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03933735Phase 1/2
• An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialActive, not recruitingNCT03844048Phase 3
• A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyWithdrawnNCT03785184Phase 2
• A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Phase 3
• A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03314181Phase 2
• A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer TreatmentWithdrawnNCT02951117Phase 1
• Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)Active, not recruitingNCT02899052Phase 2
• Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple MyelomaTerminatedNCT02462525Phase 1
• A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerCompletedNCT02391480Phase 1
• Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
• A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyCompletedNCT01794507Phase 1
• A Safety and Tolerability Study of PCI-24781 in Subjects With CancerCompletedNCT01149668Phase 1
• IMGN901 in Combination With Lenalidomide and DexamethasoneCompletedNCT00991562Phase 1
• Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer PatientsCompletedNCT00562224Phase 1
• BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT00346255Phase 1
• A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT00096837Phase 2